Fiche publication
Date publication
avril 2019
Journal
Trends in molecular medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MULLER Sylviane
Tous les auteurs :
Retnakumar SV, Muller S
Lien Pubmed
Résumé
The arsenal of effective molecules to treat patients with chronic inflammatory bowel diseases (IBDs) remains limited. These remitting-relapsing diseases have become a global health issue and new therapeutic strategies are eagerly awaited to regulate the course of these disorders. Since the association between autophagy-related gene polymorphism and an increased risk of Crohn's disease (CD) has been discovered, a new domain of investigation has emerged, focused on the intracellular degradation system, with the objective of generating new medicines that are safer and more targeted. This review summarizes the drugs administered to IBD patients and describes recently emerged therapeutic agents. We compile evidence on the contribution of autophagy to IBD pathogenesis, give an overview of pharmacological autophagy regulators in animal models of colitis, and propose novel therapeutic avenues based on autophagy components.
Mots clés
Crohn’s disease, animal models, autoinflammatory diseases, autophagy, inflammatory bowel diseases, therapeutic antibodies, therapeutic peptides, ulcerative colitis
Référence
Trends Mol Med. 2019 Apr 2;:
